|
Antibodies hold the key: Human monoclonal antibodies promise low-cost drug discovery delivering safe and effective, therapeutic candidates. (Feature).
Chemistry and Industry
|
March 4, 2002|
|
COPYRIGHT 2002 Society of Chemical Industry. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
(Hide copyright information)
Copyright
|
Developing new drugs
Every year the pharmaceutical industry spends millions of research dollars developing new chemical entities (NCEs). This process involves producing and screening vast libraries of chemical compounds and, the estimate is that it takes more than five years of pre-clinical work before an NCE can enter human clinical trials. Despite this costly R&D effort, only a limited number of NCEs actually become marketed drugs. In 2001, of 66 new drugs approved by the US Food and Drug Administration (FDA), only 24 were molecular entities that had never been ...
Find more facts and information related to the
article "Antibodies hold the key: Human monoclonal ..."
